Artelo Presents Safety, Dose-Proportional Pharmacokinetics and AI Biomarker Data for ART26.12
ARTL•Artelo’s first-in-human Phase 1 trial of ART26.12 in healthy volunteers showed dose-proportional pharmacokinetics, plasma concentrations above projected therapeutic levels, and a favorable safety profile across all cohorts. AI-driven biomarker analyses identified treatment-related changes in lipid metabolism, inflammation and phospholipid signaling to guide future dose optimization and patient selection.
1. Phase 1 Study Findings
Artelo Biosciences presented first-in-human results from a Phase 1 trial of ART26.12 at the International Cannabinoid Research Society Annual Symposium. The study evaluated single ascending oral doses in healthy volunteers, revealing a favorable safety and tolerability profile across all cohorts, linear dose-dependent pharmacokinetics and systemic exposure exceeding preclinical therapeutic thresholds. These outcomes demonstrate a wide margin between projected therapeutic levels and maximum tolerated doses, validating ART26.12’s potential as a peripherally acting, non-opioid analgesic targeting FABP5 in neuropathic pain.
